Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline in NTM pulmonary disease (M. abscessus)
NCT04922554Phase 2Completed
- Sponsor
- Paratek Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nontuberculous mycobacterial pulmonary disease (NTM-PD) comparing Omadacycline with Placebo (2 arms). Primary endpoints: Percentage of Participants With Clinical Response on NTM Symptom Assessment Scale at Day 84, Percentage of Participants With Clinical Response on NTM Symptom Assessment Scale at Day 84 With no Deterioration and 1 more. Started Oct 2021; status: completed.
02
Drugs
omadacycline
03
Conditions
nontuberculous mycobacterial pulmonary disease (NTM-PD)
Beyond the preview
Go deeper on NCT04922554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922554.